Alternative Vasodilator and Supportive Therapies for Acute Heart Failure When Nitroglycerin or Nitroprusside Are Unavailable

Nesiritide

Nesiritide is the most direct intravenous vasodilator alternative when nitroglycerin and nitroprusside are unavailable, suitable for patients with acute heart failure. 1, 3
Recommended infusion rate is 0.015–0.03 µg/kg/min, administered with or without a loading dose. 1, 2
Provides balanced venous and arterial dilation with modest diuretic and natriuretic effects. 1, 4
Does not require invasive arterial‑pressure monitoring; non‑invasive measurements are sufficient. 1, 5
Has a longer half‑life than nitroglycerin or nitroprusside, so hypotension may persist longer after discontinuation. 3
Not widely available in most European countries. 1, 2
A large randomized trial showed no reduction in mortality, rehospitalization, or renal dysfunction; it produced a small but statistically significant improvement in dyspnea and an increased risk of hypotension. 3

Isosorbide mononitrate and isosorbide dinitrate can be administered orally or intravenously as alternative nitrates. 1, 2
Oral isosorbide dinitrate is given at 1 mg or 3 mg doses. 1, 5
These agents act primarily as venodilators, similar to nitroglycerin. 1
Tachyphylaxis commonly develops after 24–48 hours, necessitating dose escalation. 1, 2

Nicardipine and clevidipine are viable vasodilator options when nitrates are unavailable, especially in hypertensive acute heart failure patients. 6, 7
Nicardipine infusion: start at 5 mg/h, titrate by 2.5 mg every 15–30 minutes to a target range of 5–15 mg/h. 6, 7
Clevidipine infusion: start at 2 mg/h, increase by 2 mg every 2 minutes until the desired blood pressure is achieved. 6, 7
Common adverse effects include headache and reflex tachycardia. 6, 7

Vasodilators should be avoided in patients with systolic blood pressure (SBP) < 90 mmHg to prevent central organ hypoperfusion. 1, 2, 4
Vasodilator therapy is recommended for patients with SBP > 110 mmHg. 1, 2
In patients with SBP 90–110 mmHg, vasodilators may be used cautiously with close monitoring. 1, 2
Particular caution is required in patients with renal dysfunction, as hypotension can exacerbate renal injury. 1, 2
Patients with aortic stenosis are at risk for marked hypotension after initiation of intravenous vasodilators. 1, 2

Inotropic agents should be considered for patients with low‑output acute heart failure who exhibit signs of hypoperfusion or congestion despite optimal vasodilator and diuretic therapy. 8, 5, 4
Indications include low SBP or low cardiac index together with clinical signs of hypoperfusion (cold, clammy skin; vasoconstriction with acidosis; worsening renal or hepatic function; altered mental status). 8, 5
Inotropes are reserved for patients with dilated, hypokinetic ventricles. 8, 5

Dobutamine is a β1‑adrenergic agonist that provides positive inotropic support. 5
Initiate as early as possible and discontinue promptly once adequate organ perfusion is restored. 8, 5, 4
Although dobutamine can improve hemodynamics acutely, it may promote pathophysiologic mechanisms that increase short‑ and long‑term mortality. 8, 5, 4

Intravenous loop diuretics remain the cornerstone of treatment for acute heart failure with volume overload, irrespective of vasodilator availability. 9, 10
Recommended initial bolus: furosemide 20–40 mg IV (or equivalent doses of bumetanide 0.5–1 mg, torsemide 10–20 mg). 10
Dose may be escalated based on renal function and chronic diuretic exposure. 10
Continuous infusion can be considered after the initial bolus. 10
Total furosemide exposure should be kept < 100 mg in the first 6 hours and < 240 mg in the first 24 hours. 10

SBP > 110 mmHg: Use vasodilators (nesiritide, alternative nitrates, or nicardipine) together with diuretics. 2
SBP 90–110 mmHg: Apply vasodilators cautiously, add diuretics, and monitor blood pressure closely. 4
SBP < 90 mmHg with hypoperfusion signs: Initiate inotropic therapy (dobutamine) plus diuretics; avoid vasodilators. 8

Conventional calcium‑channel antagonists are not recommended in the management of acute heart failure. 1, 2, 4
Nitroprusside should be avoided in acute coronary syndrome because it reduces regional coronary flow and increases myocardial injury after myocardial infarction. 6, 7
Monitor for nitrate tachyphylaxis, which typically develops after 24–48 hours and may require dose adjustments. 1, 2, 5
Titrate all vasodilators slowly and monitor blood pressure frequently to prevent abrupt SBP declines. 1, 5